Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · IEX Real-Time Price · USD
-1.21 (-1.42%)
At close: Jul 17, 2024, 4:00 PM
+0.21 (0.25%)
After-hours: Jul 17, 2024, 5:15 PM EDT

Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.

Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.

The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.
Axsome Therapeutics logo
Country United States
Founded 2012
IPO Date Nov 19, 2015
Industry Biotechnology
Sector Healthcare
Employees 545
CEO Dr. Herriot Tabuteau M.D.

Contact Details

One World Trade Center, 22nd Floor
New York, New York 10007
United States
Phone (212) 332-3241

Stock Details

Ticker Symbol AXSM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001579428
CUSIP Number 05464T104
ISIN Number US05464T1043
Employer ID 45-4241907
SIC Code 2834

Key Executives

Name Position
Dr. Herriot Tabuteau M.D. Founder, Chairman, Chief Executive Officer and President
Nick Pizzie CPA, M.B.A. Chief Financial Officer
Mark L. Jacobson Chief Operating Officer and Secretary
Hunter Murdock Esq. General Counsel and Secretary
Dr. Amanda Jones Pharm.D. Senior Vice President of Clinical Development
Lori Englebert M.B.A. Executive Vice President of Commercial and Business Development
Joseph Debrah-Afful CPA, M.B.A. Director of Finance

Latest SEC Filings

Date Type Title
Jun 11, 2024 8-K Current Report
Jun 5, 2024 8-K Current Report
May 29, 2024 144 Filing
May 29, 2024 144 Filing
May 28, 2024 144 Filing
May 6, 2024 10-Q Quarterly Report
May 6, 2024 8-K Current Report
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 1, 2024 144 Filing